PARIS--(BUSINESS WIRE)--Regulatory News:
Ikonisys SA (ISIN Code: FR00140048X2 / Mnemonic : ALIKO), a company specializing in the early and accurate detection of cancer through a unique and fully automated solution for medical diagnostic laboratories, announces that all the resolutions submitted to the Ordinary Annual and Extraordinary General Meeting held on June 28, 2023 (the "AGM") have been adopted by the shareholders, in accordance with the recommendations of the Board of Directors, and in particular the resolutions relating to the approval of the parent company and consolidated financial statements for fiscal year 2022 and the financial delegations to the Board of Directors.
With a quorum of 70.97%, i.e. 6,913,968 shares with the same number of voting rights, the Ikonisys Annual General Meeting was validly held under the chairmanship of Mr. Mario Mauri, in his capacity as Chairman of the Company's Board of Directors.
About Ikonisys
Ikonisys SA is a cell-based diagnostics company based in Paris (France), New Haven (Connecticut, USA) and Milan (Italy) specialized in the early and accurate detection of cancer. The company develops, produces and markets the proprietary Ikoniscope20® platform, a fully-automated solution designed to deliver accurate and reliable detection and analysis of rare and very rare cells. Ikonisys has received FDA clearance for several automated diagnostic applications, which are also marketed in Europe under CE certification. Through its breakthrough fluorescence microscopy platform, the company continues to develop a stream of new tests, including liquid biopsy tests based on Circulating Tumor Cells (CTC).
For further information, please go to www.Ikonisys.com